TORONTO, ONTARIO--(CCNMatthews - Nov. 6, 2006) - Orbus Pharma Inc. (TSX:ORB) (“Orbus”) today announced that it has entered into an agreement with Desitin Arzneimittel GmbH, (“Desitin”) of Germany for its immediate release 150mg, 300mg and 600mg tablets containing the active ingredient oxcarbazepine (anti-epileptic). Also party to the agreement is Orbus’ partner in this drug development, Alfred E.Tiefenbacher GmbH & Co. KG (“AET”) of Germany.
